Reviewing SeaStar Medical (NASDAQ:ICU) and CochLear (OTCMKTS:CHEOY)

CochLear (OTCMKTS:CHEOYGet Free Report) and SeaStar Medical (NASDAQ:ICUGet Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares CochLear and SeaStar Medical”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CochLear $1.53 billion 3.49 $251.85 million N/A N/A
SeaStar Medical $1.23 million 15.80 -$12.15 million ($4.80) -1.01

CochLear has higher revenue and earnings than SeaStar Medical.

Institutional and Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

CochLear has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for CochLear and SeaStar Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CochLear 0 3 1 1 2.60
SeaStar Medical 1 0 1 0 2.00

SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 64.61%. Given SeaStar Medical’s higher possible upside, analysts plainly believe SeaStar Medical is more favorable than CochLear.

Profitability

This table compares CochLear and SeaStar Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CochLear N/A N/A N/A
SeaStar Medical -828.62% -146.29% -96.48%

Summary

CochLear beats SeaStar Medical on 8 of the 12 factors compared between the two stocks.

About CochLear

(Get Free Report)

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About SeaStar Medical

(Get Free Report)

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.